CYTOKINETICS INC - 8-K Filing
Cytokinetics announced positive results from its Phase 3 ACACIA-HCM trial for aficamten in non-obstructive HCM, meeting both primary endpoints and planning an FDA submission by Q4. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CYTK